131 related articles for article (PubMed ID: 2272355)
41. Differential binding characteristics of agonists at 5-HT3 receptor recognition sites in NG108-15 neuroblastoma-glioma cells labelled by [3H]-(S)-zacopride and [3H]granisetron.
Barnes JM; Barnes NM
Biochem Pharmacol; 1993 May; 45(10):2155-8. PubMed ID: 8390263
[TBL] [Abstract][Full Text] [Related]
42. [3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain.
Waeber C; Sebben M; Grossman C; Javoy-Agid F; Bockaert J; Dumuis A
Neuroreport; 1993 Sep; 4(11):1239-42. PubMed ID: 8219020
[TBL] [Abstract][Full Text] [Related]
43. Serotonin and the mammalian circadian system: I. In vitro phase shifts by serotonergic agonists and antagonists.
Prosser RA; Dean RR; Edgar DM; Heller HC; Miller JD
J Biol Rhythms; 1993; 8(1):1-16. PubMed ID: 8490207
[TBL] [Abstract][Full Text] [Related]
44. Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography.
Fischette CT; Nock B; Renner K
Brain Res; 1987 Sep; 421(1-2):263-79. PubMed ID: 3690273
[TBL] [Abstract][Full Text] [Related]
45. Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells.
Bolaños FJ; Schechter LE; Miquel MC; Emerit MB; Rumigny JF; Hamon M; Gozlan H
Biochem Pharmacol; 1990 Oct; 40(7):1541-50. PubMed ID: 2222509
[TBL] [Abstract][Full Text] [Related]
46. Autoradiographic analysis of the distribution of vasoactive intestinal peptide binding sites in the vertebrate central nervous system: a phylogenetic study.
Dietl MM; Hof PR; Martin JL; Magistretti PJ; Palacios JM
Brain Res; 1990 Jun; 520(1-2):14-26. PubMed ID: 2169952
[TBL] [Abstract][Full Text] [Related]
47. [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.
Bonhaus DW; Loury DN; Jakeman LB; To Z; DeSouza A; Eglen RM; Wong EH
J Pharmacol Exp Ther; 1993 Nov; 267(2):961-70. PubMed ID: 8246171
[TBL] [Abstract][Full Text] [Related]
48. Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains.
Inagaki S; Kito S; Kubota Y; Girgis S; Hillyard CJ; MacIntyre I
Brain Res; 1986 May; 374(2):287-98. PubMed ID: 3013366
[TBL] [Abstract][Full Text] [Related]
49. Identification of 5-HT3 binding sites in rat spinal cord synaptosomal membranes.
Glaum SR; Anderson EG
Eur J Pharmacol; 1988 Nov; 156(2):287-90. PubMed ID: 3240771
[TBL] [Abstract][Full Text] [Related]
50. Characterisation of 5-HT3 recognition sites in membranes of NG 108-15 neuroblastoma-glioma cells with [3H]ICS 205-930.
Neijt HC; Karpf A; Schoeffter P; Engel G; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1988 May; 337(5):493-9. PubMed ID: 3412489
[TBL] [Abstract][Full Text] [Related]
51. The cardiovascular effects of quipazine are mediated by peripheral 5-HT2 and 5-HT3 receptors in anaesthetized rats.
Vayssettes-Courchay C; Bouysset F; Verbeuren TJ; Laubie M; Schmitt H
Eur J Pharmacol; 1990 Aug; 184(1):75-85. PubMed ID: 2120077
[TBL] [Abstract][Full Text] [Related]
52. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain.
Lucaites VL; Krushinski JH; Schaus JM; Audia JE; Nelson DL
Naunyn Schmiedebergs Arch Pharmacol; 2005 Mar; 371(3):178-84. PubMed ID: 15900511
[TBL] [Abstract][Full Text] [Related]
53. Characterization of 5-HT3 and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro.
Eglen RM; Swank SR; Walsh LK; Whiting RL
Br J Pharmacol; 1990 Nov; 101(3):513-20. PubMed ID: 2076474
[TBL] [Abstract][Full Text] [Related]
54. [3H]5-methyl-urapidil labels 5-HT1A receptors and alpha 1-adrenoceptors in the rat CNS. In vitro binding and autoradiographic studies.
Laporte AM; Schechter LE; Bolaños FJ; Vergé D; Hamon M; Gozlan H
Eur J Pharmacol; 1991 May; 198(1):59-67. PubMed ID: 1680714
[TBL] [Abstract][Full Text] [Related]
55. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
Cappelli A; Anzini M; Vomero S; Mennuni L; Makovec F; Doucet E; Hamon M; Bruni G; Romeo MR; Menziani MC; De Benedetti PG; Langer T
J Med Chem; 1998 Feb; 41(5):728-41. PubMed ID: 9513601
[TBL] [Abstract][Full Text] [Related]
56. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.
Kilpatrick GJ; Jones BJ; Tyers MB
Nature; 1987 Dec 24-31; 330(6150):746-8. PubMed ID: 3696238
[TBL] [Abstract][Full Text] [Related]
57. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
[TBL] [Abstract][Full Text] [Related]
58. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
Titeler M; Lyon RA; Davis KH; Glennon RA
Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239
[TBL] [Abstract][Full Text] [Related]
59. Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study.
Glennon RA; Ismaiel AE; McCarthy BG; Peroutka SJ
Eur J Pharmacol; 1989 Sep; 168(3):387-92. PubMed ID: 2583244
[TBL] [Abstract][Full Text] [Related]
60. Central 5-HT3 receptors in P and in AA alcohol-preferring rats: An autoradiographic study.
Ciccocioppo R; Ge J; Barnes NM; Cooper SJ
Brain Res Bull; 1998 Jul; 46(4):311-5. PubMed ID: 9671260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
